Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | NT5E | P21589 | 2/20 | 0.63 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | GLI1 | P08151 | 2/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.58 |
| ▸ | ALB | P02768 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | DPP4 | P27487 | 1/20 | 0.58 |
| ▸ | RORC | P51449 | 1/20 | 0.58 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.58 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18124324 | 1.00 | LMNA (0.63) | LMNANT5EGPBAR1SMN1; SMN2GLI1 | |
| SCHEMBL18124326 | 1.00 | LMNA (0.63) | LMNANT5EGPBAR1SMN1; SMN2GLI1 | |
| SCHEMBL9888523 | 0.94 | LMNA (0.55) | LMNANT5EGPBAR1SMN1; SMN2 | |
| SCHEMBL14682840 | 0.93 | LMNA (0.63) | LMNANT5EGPBAR1SMN1; SMN2GLI1 | |
| SCHEMBL9107874 | 0.93 | — | — | |
| SCHEMBL9888601 | 0.93 | — | — | |
| SCHEMBL14682807 | 0.93 | LMNA (0.62) | LMNANT5EGPBAR1SMN1; SMN2 | |
| SCHEMBL9106661 | 0.92 | LMNA (0.61) | LMNANT5EGPBAR1SMN1; SMN2GLI1 | |
| SCHEMBL9106598 | 0.92 | LMNA (0.61) | LMNANT5EGPBAR1SMN1; SMN2GLI1 | |
| SCHEMBL9889520 | 0.92 | LMNA (0.61) | LMNANT5EGPBAR1SMN1; SMN2GLI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754068-B2 | Modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754068-B2 | Modified C-3 betulinic acid derivatives as HIV maturation inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120142707-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142707-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| WO-2011153315-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142707-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BET1, BIRC3, CYTH3 | LMNA 1373/4885NT5E 2427/4885GPBAR1 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.